My independent and collaborative cancer prevention and research focuses on developing, evaluating and implementing innovative theory-driven multi-level interventions to increase use of evidence-based tobacco treatments and promote tobacco cessation, particularly in cancer patients, low income smokers, and other vulnerable populations. Since 1999, I have served as Founder and Director of Memorial Sloan-Kettering’s Tobacco Cessation Program, a hospital-based, cessation program for tobacco dependent cancer patients serving over 2500 patients annually. I have published 129 peer-reviewed papers demonstrating specific expertise in the assessment and treatment of tobacco dependence as well as tobacco-related health disparities, with specific expertise in the psychological and behavioral issues associated with prevention, early detection and long-term follow-up care of patients with tobacco-related cancers. Through my leadership roles as the Chief of the Behavioral Sciences Service and the Scientific Director of the Behavioral Research Methods Core Facility, I am strongly committed to providing research support for new investigators. I currently serve as senior faculty mentor for eight junior faculty members, several of whom have been successful in getting career development awards. I lead a behavioral sciences research team dedicated to developing and evaluating innovative theory-driven interventions to enhance quitting motivation, and increasing use of evidence-based, cessation treatments, particularly in vulnerable populations. My research has been well-supported by R01s and other peer-reviewed grants from the NCI, NIDCR, NIDA, the Robert Wood Johnson Foundation, the American Cancer Society, the Lance Armstrong Foundation and the Legacy Foundation. I serve as Co-Leader for the New York State supported Queens Quits! Tobacco Cessation Center, providing training and technical assistance in treating tobacco dependence to health care providers in Queens County, New York. I have served on numerous regional and national tobacco control committees including the American Society of Clinical Oncology Tobacco Committee, the American Cancer Society Taskforce on Tobacco Control and most recently the NCI/AACR Taskforce on Tobacco Use Assessment in Cancer Clinical Trials. I am recognized as a national leader on the assessment and treatment of tobacco use in comorbid populations (with specific expertise with tobacco dependent cancer patients and lung cancer screening) as evidenced by my active membership on an NCI/AACR Task Force on Assessment of Tobacco Use, the ASCO Tobacco Control Subcommittee of Cancer Prevention Committee, Invited Keynote Speaker (Integration of Smoking Cessation in Lung Cancer Screening) at the recent IASLC Conference in Denver, CO and member of the Lung Cancer Alliance’s Medical and Professional Advisory Board. I recently served on an NCI Task Force identifying Priorities for Tobacco Research in the Next Decade. Since her recent appointment to the Sophie Davis/CCNY faculty in January, 2012, I have worked closely with Dr. Sheffer to formulate collaborative lines of research addressing observed disparities in tobacco cessation outcomes. I serve with her on the Board of Directors of the Association for the Treatment of Tobacco Use and Dependence (ATTUD).The proposed planning grant reflects our efforts to develop a shared infrastructure for the development and implementation of research addressing tobacco-related cancer disparities. In summary, I have a demonstrated record of successful and productive research, training and clinical activities that are highly relevant to the proposed project.
[hungryfeed url=”http://www.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1NosRw4HLZNZZRZOUG0dc8xhqIBaT8KZJXBb_xIbb0mrXYc9Ro” feed_fields=”” link_target=”_blank” truncate_description=”800″ max_items=”1″]More Publications